Exploring Prognostic Markers for Patients With COVID-19 in a Low-Resource Setting: A Cross-Sectional Study

IF 2.2 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

International Journal of Clinical Practice Pub Date : 2025-04-26 DOI:10.1155/ijcp/5595869

Md. Asaduzzaman, Mohammad Romel Bhuia, Mohammad Zabed Jillul Bari, Z. H. M. Nazmul Alam, Ranjon Kumer Roy, Soumitra Roy, Goutam Talukder, M. M. Jahangir Alam, Md. Shafiqul Bari

{"title":"Exploring Prognostic Markers for Patients With COVID-19 in a Low-Resource Setting: A Cross-Sectional Study","authors":"Md. Asaduzzaman, Mohammad Romel Bhuia, Mohammad Zabed Jillul Bari, Z. H. M. Nazmul Alam, Ranjon Kumer Roy, Soumitra Roy, Goutam Talukder, M. M. Jahangir Alam, Md. Shafiqul Bari","doi":"10.1155/ijcp/5595869","DOIUrl":null,"url":null,"abstract":"<div>\n Aim: Triaging patients based on prognostic biomarkers may contribute to better management of at-risk patients in resource-constrained settings. This study aimed to explore readily available and cost-effective predictors of mortality among COVID-19 patients.\n Methods: This cross-sectional study, conducted across multiple centers, involved patients with COVID-19 admitted to four hospitals in Bangladesh. The analysis encompassed demographic information, clinical features, laboratory findings, and in-hospital outcomes. Logistic regression was utilized to identify factors contributing to mortality risk.\n Results: Among 442 patients, 55 (12.44%) experienced mortality. The patients’ mean was 60 ± 14 years. DM (76% vs. 62%), IHD (42% vs. 19%), CKD (35% vs. 15%), and COPD (24% vs. 11%) were the most prevalent comorbidities in nonsurvivors. Compared to the survivor group, median NLR (7 vs. 4.1; p = 0.005), ferritin (507 vs. 328; p = 0.21), and D-dimer (900 vs. 567; p = 0.12) were higher in the nonsurvivor group. Higher age (OR = 1.05; 95% CI = 1.02–1.08), coexisting CKD (OR = 2.59; 95% CI = 1.27–5.29), leukocytosis (OR = 2.52; 95% CI = 1.21–5.28), thrombocytopenia (OR = 0.27; 95% CI = 0.12–0.61), lower SpO2 upon admission (OR = 0.92; 95% CI = 0.89–0.95), and more extensive lung involvement on CT (OR = 1.01; 95% CI = 1.001–1.03) were significant risk factors of in-hospital death.\n </div>","PeriodicalId":13782,"journal":{"name":"International Journal of Clinical Practice","volume":"2025 1","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ijcp/5595869","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/ijcp/5595869","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: Triaging patients based on prognostic biomarkers may contribute to better management of at-risk patients in resource-constrained settings. This study aimed to explore readily available and cost-effective predictors of mortality among COVID-19 patients.

Methods: This cross-sectional study, conducted across multiple centers, involved patients with COVID-19 admitted to four hospitals in Bangladesh. The analysis encompassed demographic information, clinical features, laboratory findings, and in-hospital outcomes. Logistic regression was utilized to identify factors contributing to mortality risk.

Results: Among 442 patients, 55 (12.44%) experienced mortality. The patients’ mean was 60 ± 14 years. DM (76% vs. 62%), IHD (42% vs. 19%), CKD (35% vs. 15%), and COPD (24% vs. 11%) were the most prevalent comorbidities in nonsurvivors. Compared to the survivor group, median NLR (7 vs. 4.1; p = 0.005), ferritin (507 vs. 328; p = 0.21), and D-dimer (900 vs. 567; p = 0.12) were higher in the nonsurvivor group. Higher age (OR = 1.05; 95% CI = 1.02–1.08), coexisting CKD (OR = 2.59; 95% CI = 1.27–5.29), leukocytosis (OR = 2.52; 95% CI = 1.21–5.28), thrombocytopenia (OR = 0.27; 95% CI = 0.12–0.61), lower SpO2 upon admission (OR = 0.92; 95% CI = 0.89–0.95), and more extensive lung involvement on CT (OR = 1.01; 95% CI = 1.001–1.03) were significant risk factors of in-hospital death.

Abstract Image

查看原文本刊更多论文

在低资源环境中探索COVID-19患者的预后标志物：一项横断面研究

目的：根据预后生物标志物对患者进行分诊可能有助于在资源受限的情况下更好地管理高危患者。本研究旨在探索COVID-19患者中现成且具有成本效益的死亡率预测指标。方法：这项跨多个中心进行的横断面研究涉及孟加拉国四家医院收治的COVID-19患者。分析包括人口统计信息、临床特征、实验室结果和住院结果。采用Logistic回归分析确定导致死亡风险的因素。结果：442例患者中，死亡55例（12.44%）。患者平均年龄为60±14岁。糖尿病（76%对62%）、IHD（42%对19%）、CKD（35%对15%）和COPD（24%对11%）是非幸存者中最常见的合并症。与幸存者组相比，中位NLR(7比4.1；P = 0.005)，铁蛋白(507 vs. 328；p = 0.21)， d -二聚体(900 vs. 567；P = 0.12)高于非幸存者组。年龄越大(OR = 1.05；95% CI = 1.02-1.08)，并存CKD (OR = 2.59；95% CI = 1.27-5.29)，白细胞增多症(OR = 2.52；95% CI = 1.21 - -5.28)、血小板减少(OR = 0.27;95% CI = 0.12-0.61)，入院时SpO2较低(OR = 0.92；95% CI = 0.89-0.95)， CT上更广泛的肺部受累(OR = 1.01；95% CI = 1.001 ~ 1.03)是院内死亡的重要危险因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Clinical Practice 医学-医学：内科

CiteScore

5.30

自引率

0.00%

发文量

274

审稿时长

3-8 weeks

期刊介绍： IJCP is a general medical journal. IJCP gives special priority to work that has international appeal. IJCP publishes: Editorials. IJCP Editorials are commissioned. [Peer reviewed at the editor''s discretion] Perspectives. Most IJCP Perspectives are commissioned. Example. [Peer reviewed at the editor''s discretion] Study design and interpretation. Example. [Always peer reviewed] Original data from clinical investigations. In particular: Primary research papers from RCTs, observational studies, epidemiological studies; pre-specified sub-analyses; pooled analyses. [Always peer reviewed] Meta-analyses. [Always peer reviewed] Systematic reviews. From October 2009, special priority will be given to systematic reviews. [Always peer reviewed] Non-systematic/narrative reviews. From October 2009, reviews that are not systematic will be considered only if they include a discrete Methods section that must explicitly describe the authors'' approach. Special priority will, however, be given to systematic reviews. [Always peer reviewed] ''How to…'' papers. Example. [Always peer reviewed] Consensus statements. [Always peer reviewed] Short reports. [Always peer reviewed] Letters. [Peer reviewed at the editor''s discretion] International scope IJCP publishes work from investigators globally. Around 30% of IJCP articles list an author from the UK. Around 30% of IJCP articles list an author from the USA or Canada. Around 45% of IJCP articles list an author from a European country that is not the UK. Around 15% of articles published in IJCP list an author from a country in the Asia-Pacific region.